## RMD: ResMed Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -2.1% below STRENGTH zone (4.0-10.0%); PEG 1.57 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($234.84)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Thrivent Financial for Lutherans Acquires 5,212 Shares of ResMed Inc. $RMD**
- Source: MarketBeat | 20251222T100948 | Somewhat-Bullish | Relevance: 100%
- Thrivent Financial for Lutherans significantly increased its stake in ResMed Inc. by 75.7% in Q2, acquiring an additional 5,212 shares, bringing its total holdings to 12,099 shares valued at $3.11 million. Despite this institutional accumulation, company insiders, including a director and the CEO, collectively sold 22,662 shares worth approximately $5.95 million in the last 90 days. ResMed recently surpassed earnings estimates and maintains a "Moderate Buy" consensus rating with an average target price of $296.09 from analysts.

**2. Texas Permanent School Fund Corp Sells 5,560 Shares of ResMed Inc. $RMD**
- Source: MarketBeat | 20251221T103416 | Somewhat-Bullish | Relevance: 100%
- Texas Permanent School Fund Corp significantly reduced its stake in ResMed Inc. (NYSE:RMD) by 35%, selling 5,560 shares and holding 10,310 shares valued at $2.66 million. Analysts have a "Moderate Buy" consensus for RMD with an average price target of $296.09, despite some recent target trims. ResMed recently surpassed EPS estimates and increased revenue by 9.1%, paying a $0.60 quarterly dividend, while insiders have been net sellers of the stock.

**3. ResMed Inc. $RMD Shares Acquired by Addenda Capital Inc.**
- Source: MarketBeat | 20251220T060836 | Bullish | Relevance: 100%
- Addenda Capital Inc. increased its stake in ResMed (NYSE:RMD) by 41.6% in the third quarter, now owning 77,456 shares worth $21.2 million. Institutional investors collectively own 54.98% of the company, with Vanguard Group Inc. holding a significant portion. ResMed has received a "Moderate Buy" consensus rating from Wall Street analysts, with a target price of $296.09, and the company recently reported strong quarterly earnings and pays a $0.60 quarterly dividend.

**4. Squarepoint Ops LLC Trims Holdings in CECO Environmental Corp. $CECO**
- Source: MarketBeat | 20251222T100911 | Neutral | Relevance: 59%
- Squarepoint Ops LLC significantly reduced its stake in CECO Environmental Corp. ($CECO) by 63.3%, selling 67,716 shares and retaining 39,251 shares valued at $1.11 million. Despite this, CECO Environmental reported strong Q2 earnings, beating analyst estimates with $0.26 EPS and 45.8% year-over-year revenue growth. Institutional ownership remains high at 68.08%, with an average analyst target price near $56.20 and several recent "Buy" ratings.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Stifel | $260 | $270 | -4% |
| 2025-12-16 | Baird | $275 | $300 | -8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Stifel | main | Hold |
| 2025-12-16 | Baird | down | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 16 ($9.01M) |
| Sells | 17 ($5.01M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Vanguard Group Inc: 13.1% (+1.6%)
- Blackrock Inc.: 8.4% (-1.3%)
- State Street Corpora: 4.5% (-1.0%)
- Bank Of New York Mel: 3.1% (-9.8%)
- Geode Capital Manage: 2.9% (+0.9%)

### Key Risks

1. Insider selling cluster: $5.0M in recent transactions.
2. Elevated short interest (8.2%): bears positioning against stock.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.57 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 25%, ROA 14%, margin 27%). Balance sheet: strong liquidity (2.9x), low leverage (D/E 0.36). Analyst sentiment negative (2 target cuts vs 0 raises). Institutional flow bullish (3 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $36.0B |
| Beta | 0.87 |
| 52W Range | $199.92 - $293.81 |
| Short Interest | 8.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.57 |
| Forward P/E | 20.5 |
| Current P/E | 22.6 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 weakening modestly (-0.8% over 5 days). Below STRENGTH zone by 6.1pp (needs >4.0% for momentum thesis). Below SMA200 (0.97x), long-term trend not supportive. RSI neutral at 44. Elevated volume (1.7x 20MA), institutional activity likely. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.11% (CS: 26) | Weak |
| RSI_14 | 44.5 | Neutral |
| MACD Histogram | -0.36 | Bearish |
| vs SMA20 | 0.985x | Below |
| vs SMA50 | 0.972x | Below |
| vs SMA200 | 0.972x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $246.60
- **Stop Loss:** $234.84 (4.8% risk)
- **Target:** $258.36 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 102
- **Position Value:** $25,153.20
- **Portfolio %:** 25.15%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-05 (Est: $2.71)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.50 | $2.55 | +2.0% |
| 2025Q2 | $2.48 | $2.55 | +2.8% |
| 2025Q1 | $2.36 | $2.37 | +0.4% |
| 2024Q4 | $2.31 | $2.43 | +5.0% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*